Compare SMG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMG | CELC |
|---|---|---|
| Founded | 1868 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | SMG | CELC |
|---|---|---|
| Price | $57.83 | $102.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $69.50 | ★ $100.13 |
| AVG Volume (30 Days) | 734.2K | ★ 959.5K |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $3,413,100,000.00 | N/A |
| Revenue This Year | $1.34 | N/A |
| Revenue Next Year | $2.23 | N/A |
| P/E Ratio | $23.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.61 | $7.58 |
| 52 Week High | $79.12 | $112.64 |
| Indicator | SMG | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 64.20 |
| Support Level | $52.06 | $100.00 |
| Resistance Level | $57.23 | $112.64 |
| Average True Range (ATR) | 1.67 | 5.11 |
| MACD | 0.34 | -0.99 |
| Stochastic Oscillator | 94.70 | 37.95 |
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The business consists of three reporting segments: US consumer, Hawthorne, and other. The US consumer segment consists of a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Hawthorne sells indoor gardening and hydroponic equipment, particularly to the cannabis growing industry, while the other segment primarily consists of lawn and gardening products sold in Canada. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.